Clinical Trial Update: A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study evaluated the combination of OSI-906 and Erlotinib (Tarceva) in patients with advanced solid tumors; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• OSI-906 (OSI-906)
• Tarceva (erlotinib)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED